Industry News
Positive Feedback And Tumorigenesis
Jan 02, 2012
Cancer cells are essentially immortal. The acquisition of an unlimited capacity to divide - the process of immortalization - is a central event in the genesis of tumors. Normally, cells are subject to stringent mechanisms which control their proliferation. Together these ensure that pre-malignant cells are induced to enter a senescent, non-dividing state or to undergo apoptosis, i.e... Read More
Gene Links Rare And Unrelated Cancers
Jan 02, 2012
Scientists at the BC Cancer Agency, Vancouver Coastal Health Research Institute, and the University of British Columbia are excited over a discovery made while studying rare tumour types. Dr. David Huntsman, genetic pathologist and director of the Ovarian Cancer Program of BC at the BC Cancer Agency and Vancouver Coastal Health Research Institute and Dr... Read More
Lung Cancer Alliance Calls 2011 "The Turning Point"
Jan 01, 2012
Lung Cancer Alliance (LCA) President Laurie Fenton-Ambrose predicted that because of major breakthroughs this year in screening, treatment and research, 2011 will be defined as the turning point year for lung cancer... Read More
Roswell Park Researcher Aims To Develop Screening Test For Lung Cancer
Jan 01, 2012
Lung cancer takes a heavy toll, contributing to more cancer deaths in the United States each year than breast, prostate and colon cancers combined. Contributing to this poor prognosis is the fact that lung cancer often goes undetected until the disease has reached an advanced and more difficult-to-treat stage... Read More
Ring In A New Healthier You In 2012
Jan 01, 2012
With the start of a new year, Dana-Farber Cancer Institute experts are encouraging people to ring in new healthy habits and offer a number of free and low-cost strategies to help people maintain good health and possibly reduce various cancer risks. Get moving! Staying fit and healthy can be as simple as lacing up a pair of sneakers and going for a walk... Read More
Jennerex Announces First Patient Treated In Phase 2a Clinical Trial Of JX-594 As A Neoadjuvant Therapy In Colorectal Cancer
Jan 01, 2012
Jennerex, Inc., a private clinical-stage biotherapeutics company focused on the development and commercialization of first-in-class targeted oncolytic virus products for cancer, announced that the first patient has been treated in a Phase 2a clinical trial of JX-594 as a neoadjuvant therapy in patients who are undergoing surgery to treat colorectal cancer that has spread to the liver... Read More
Self-Regulation Of The Immune System Suppresses Defense Against Cancer
Jan 01, 2012
It is vital that the body's own immune system does not overreact. If its key players, the helper T cells, get out of control, this can lead to autoimmune diseases or allergies. An immune system overreaction against infectious agents may even directly damage organs and tissues... Read More
FDA To Review Potential New Use Of XGEVA® (Denosumab) At Oncologic Drugs Advisory Committee Meeting
Dec 31, 2011
Amgen (NASDAQ: AMGN) announced the U.S. Food and Drug Administration (FDA) has invited the Company to participate in a meeting of the Oncologic Drugs Advisory Committee (ODAC) on Feb. 8, 2012 to discuss the supplemental Biologics License Application (sBLA) for XGEVA® (denosumab) to treat men with castration-resistant prostate cancer (CRPC) at high risk of developing bone metastases... Read More
Cellular-Imaging Center Gets Over $8 Million To Speed Search For Earlier Diagnostic Tests And Treatments For Cancer
Dec 30, 2011
A team of cancer imaging experts at Johns Hopkins has embarked on a five-year research initiative to speed development of early diagnostic tests and new treatments for breast, prostate and other common cancers... Read More
Cellular-Imaging Center Gets Over $8 Million To Speed Search For Earlier Diagnostic Tests And Treatments For Cancer
Dec 29, 2011
A team of cancer imaging experts at Johns Hopkins has embarked on a five-year research initiative to speed development of early diagnostic tests and new treatments for breast, prostate and other common cancers... Read More
Previous Page Next Page